Clinical-stage biotechnology company
Appears in 3 stories
Developer of Rentosertib; sponsor of GENESIS-IPF-3
Insilico Medicine dosed the first patient this week in a Phase III trial of Rentosertib, a drug for the progressive lung disease idiopathic pulmonary fibrosis. It's the first medicine with both an AI-identified target and an AI-designed molecule to reach this stage of testing.
Updated Yesterday
Publicly listed on the Hong Kong exchange; releasing frontier specialist AI models
Insilico Medicine released AI models Sept. 2 that it says outperform the dedicated software drug companies have used for years. The language-model specialists cover chemical synthesis, drug-safety prediction, and target-binding strength.
Updated Sep 4
Lead clinical-stage AI drug developer; Phase III for rentosertib expected Q4 2026; signed $2.5 billion neuroimmune collaboration with SK Biopharmaceuticals in June 2026
In January 2026, Tsinghua University researchers published DrugCLIP in Science, a system that screened 500 million drug compounds against 10,000 human proteins in under 24 hours on eight GPUs. The approach is 10 million times faster than conventional molecular docking, and the results are public in GenomeScreenDB, covering roughly half the human genome.
Updated Jun 27
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
